Citations

Clear

83 citation(s) found for "Shen, Win".

Role of Colchicine in Reducing Atrial Fibrillation Recurrence After Catheter Ablation
Kanaan, Christopher , Ibrahim, Ramzi , Pham, Hoang Nhat , Abdelnabi, Mahmoud , Habib, Eiad , Farina, Juan M. , Narayanasamy, Hemalatha , Chahal, C. Anwar A. , Arsanjani, Reza , Shen, Win‐Kuang , Masry, Hicham El , Sorajja, Dan , Kanaan, Christopher N , Farina, Juan M , Narayanasamy, Hema , Chahal, Choudhary Anwar A , El Masry, Hicham , Arsanjani, Reza , Nhat, Hoang , Ibrahim, Ramzi

Mayo Clinic

Journal of the American Heart Association | August 23, 2025 | Volume: 14 | Issue: 17 | Pages: No page available

10.1161/jaha.125.041827 | PMID 40847498 Get It

The hope and the hype of artificial intelligence for syncope management
Johnston, Samuel L. , Barsotti, Ercole John , Fedorowski, Artur , Ricci, Fabrizio , Heller, Eric G, Sheldon, Robert S. , Sutton, Richard , Shen, Win‐Kuang , Thiruganasambandamoorthy, Venkatesh , Adhaduk, Mehul , Parker, William H. , Aburizik, Arwa , Haselton, Corey R, Cuskey, Alex J, Johansson, Madeleine , Dominic, Paari , Rao, B. Hygriv , Mudireddy, Avinash , Statz, Giselle M., Benditt, David G. , Gatti, Mauro , Menè, Roberto , Shiffer, Dana , Vassilikos, Vassilios , Bakogiannis, Constantinos , Fedorowski, Artur , Ricci, Fabrizio , Sheldon, Robert , Sutton, Richard , Shen, Win-Kuang , Thiruganasambandamoorthy, Venkatesh , Adhaduk, Mehul , Parker, William H , Aburizik, Arwa , Lee, Sangil , Johansson, Madeleine , Macfarlane, Donald , Dominic, Paari , Abe, Haruhiko , Rao, B Hygriv , Mudireddy, Avinash , Sonka, Milan , Sandhu, Roopinder K , Kenny, Rose Anne , Gopinathannair, Rakesh , Benditt, David , Dipaola, Franca , Gatti, Mauro , Giaj Levra, Alessandro , Furlan, Raffaello , Ruwald, Martin H , Vassilikos, Vassilios , Gebska, Milena A , Olshansky, Brian , Cuskey, Alex, Lee, Sangil , Kenny, Rose Anne , Gopinathannair, Rakesh , Dipaola, Franca , Costantino, Giorgio , Furlan, Raffaello , Olshansky, Brian

Mayo Clinic

European Heart Journal - Digital Health | June 25, 2025 | Volume: 6 | Issue: 5 | Pages: 1046-1054

10.1093/ehjdh/ztaf061 | PMID 40984999 Get It

Abstract Aims Syncope remains a diagnostic challenge despite advancements in testing and treatment. Cardiac syncope is an independent predictor of mortality and can be difficult to distinguish from other causes of transient loss of consciousness (TLOC). This paper explores whether artificial intelligence (AI) can improve the evaluation and management of patients with syncope. Methods and results We conducted a literature review and incorporated the opinions of experts in the fields of syncope and AI. The cause of TLOC is often unclear, hospitalization criteria are ambiguous, diagnostic tests are frequently non-informative, and assessments are costly. Patients are left with unanswered questions and limited guidance. Artificial intelligence (AI) has the potential to optimize syncope evaluation by processing large data sets, detecting imperceptible patterns, and assisting clinicians. However, AI has limitations, including errors, lack of human empathy, and uncertain clinical utility. Liability issues further complicate its integration. We present three viewpoints: (i) AI is crucial for advancing syncope management; (ii) AI can enhance the patient experience; and (iii) AI in syncope care is inevitable. Conclusion Artificial intelligence may improve syncope diagnosis and management, particularly through machine learning–based test interpretation and wearable device data. However, it has yet to surpass human clinical judgment in complex decision-making. Current challenges include gaps in understanding syncope mechanisms, AI interpretability, generalizability, and clinical integration. Standardized diagnostic approaches, real-world validation, and curated data sets are essential for progress. Artificial intelligence may enhance efficiency and communication but raises concerns regarding confidentiality, bias, inequities, and legal implications.
Safety and Efficacy of Pulsed Field Ablation for Cavotricuspid Isthmus‐Dependent Flutter: A Systematic Literature Review
Rodriguez, Juan F. , Muthu, Padmapriya , Prajapati, Poojan , Shen, Win‐Kuang , Valverde, Arturo M. , Rodriguez-Riascos, Juan F , Vemulapalli, Hema Srikanth , Muthu, Padmapriya , Su, Wilber , Srivathsan, Komandoor

Mayo Clinic

Journal of Cardiovascular Electrophysiology | May 28, 2025 | Volume: 36 | Issue: 8 | Pages: 2013-2024

10.1111/jce.16719 | PMID 40434140 Get It

ABSTRACT Cavotricuspid isthmus ablation (CTI) is a first‐line therapy in patients with typical atrial flutter. With the advent of pulsed field (PF) as a new energy source, we sought to evaluate the use of PF for CTI ablation. A systematic literature search was conducted on the use of PF for CTI‐flutter up to December 2024. A meta‐analysis was performed for studies reporting pooled data, while individual case reports were reviewed and summarized. The mean number of PF applications, acute success rate, and prevalence of coronary vasospasm were evaluated. Eleven studies with pooled data from 155 patients were included. All patients had an acute block of the CTI. The mean number of PFA applications was 7.78 (95% CI 6.53–9.48). The incidence of ST‐elevation was 0.04% (95% CI 0–2.23%). Subclinical vasospasm was documented in 45% (95% CI 32%–59%) of patients who underwent periprocedural coronary angiography. Prophylactic use of nitrates showed a trend toward reducing the incidence of subclinical vasospasm (RR 0.24, 95% CI 0.06–1.06, p = 0.059). Twelve cases with patient‐level data were included; six reported complications, including ST elevation and conduction disturbances. PFA for CTI flutter demonstrates high acute success; however, evidence regarding the durability of the block is limited. Clinical vasospasm with ST segment elevation is uncommon but can lead to life‐threatening complications. The incidence of subclinical vasospasm is high, and nitrates tend toward reducing this phenomenon. To date, the role of PFA for this condition appears to be limited.
Safety and Efficacy of Pulsed Field Ablation for Cavotricuspid Isthmus-Dependent Flutter: A Systematic Literature Review
Rodriguez, Juan F. , Muthu, Padmapriya , Prajapati, Poojan , Su, Felice , Shen, Win K., Valverde, Arturo M. , Rodriguez-Riascos, Juan F , Muthu, Padmapriya , Vemulapalli, Hema Srikanth , Su, Wilber , Srivathsan, Komandoor

Mayo Clinic

No container title available | March 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.174275286.60150110/v1 Get It

Background: Cavotricuspid isthmus ablation (CTI) is a first line therapy in patients with typical atrial flutter. With the advent of Pulsed Field (PF) as a new energy source, we sought to evaluate the use of PF for CTI ablation. A systematic literature search was conducted on the use of PF for CTI-flutter up to December 2024. A meta-analysis was performed for studies reporting pooled data, while a patient-level summary was done for reports with available individual data. The mean number of PF applications, acute success rate, and prevalence of coronary vasospasm were evaluated. Results: Eleven studies with pooled data from 155 patients were included. All patients had an acute block of the CTI. The mean number of PFA applications was 7.78 (95% CI 6.53–9.48). The incidence of ST-elevation was 0.04% (95% CI 0-2.23%). Subclinical vasospasm was documented in 45% (95% CI 32%–59%) of patients who underwent periprocedural coronary angiography. Prophylactic use of nitrates showed a trend toward reducing the incidence of subclinical vasospasm (RR 0.24, 95% CI 0.06–1.06, p=0.059). Twelve cases with patient-level data were included; six reported complications, including ST elevation and conduction disturbances. Conclusion: PFA for CTI flutter demonstrates high acute success; however, evidence regarding the durability of the block is limited. Clinical vasospasm with ST segment elevation is uncommon but can lead to life-threatening complications. The incidence of subclinical vasospasm is high, and nitrates trend toward reducing this phenomenon. To date, the role of PFA for this condition appears to be limited.
Paroxysmal, Persistent, and Permanent Type-1 Brugada Pattern: Does Burden Matter?
Yinadsawaphan, Thanaboon , Kulthamrongsri, Narathorn , Shen, Win‐Kuang , Sorajja, Dan , Rattanawong, Pattara , Kulthamrongsri, Narathorn , Sorajja, Dan , Rattanawong, Pattara

Mayo Clinic

Journal of Cardiovascular Development and Disease | February 12, 2025 | Volume: 12 | Issue: 2 | Pages: 65

10.3390/jcdd12020065 | PMID 39997499 Get It

Spontaneous type-1 Brugada patterns are associated with an elevated risk of major arrhythmic events, yet the relationship between varying degrees of pattern burden and the occurrence of a first major arrhythmic event remains unclear. This retrospective cohort study included 64 adult patients with a spontaneous type-1 Brugada pattern, who were identified at Mayo Clinic sites and followed for ≥12 months after the initial diagnosis. All patients underwent at least three 12-lead electrocardiograms (ECGs) within the first year. Individuals with prior major arrhythmic events were excluded. The percentage of ECGs showing a type-1 pattern was calculated and categorized as paroxysmal (<50%), persistent (50–99%), or permanent (100%). During a median follow-up of 92 months, seven patients (11%) experienced their first major arrhythmic event. Of these, one had paroxysmal, four had persistent, and two had permanent spontaneous type-1 Brugada patterns. Although statistical significance was not reached, the hazard ratios suggested a trend toward increased risk with persistent and permanent patterns compared to paroxysmal patterns. No sudden cardiac deaths occurred during follow-up. These findings suggest that a higher burden of spontaneous type-1 Brugada patterns may be associated with increased arrhythmic risk.
Elevated lipoprotein(a) levels linked to new-onset atrial fibrillation: insights from a retrospective cohort study
Kamel, Moaz, Mahmoud, Ahmed , Badr, Amro , Pereyra, Milagros , Scalia, Isabel G. , Ali, Nima Baba , Alsidawi, Said , Lester, Steven J., Rmilah, Anan Abu, Barry, Timothy, Shen, Win K., Scott, Luis R. , Masry, Hicham El , Valverde, Arturo M. , Sorajja, Dan , Ayoub, Chadi , Arsanjani, Reza , Mahmoud, Ahmed K , Pereyra Pietri, Milagros, Alsidawi, Said , Sardana, Mayank , Sorajja, Dan , Ayoub, Chadi , Arsanjani, Reza , El Masry, Hicham , Pereyra, Milagros , Scalia, Isabel G , Awad, Kamal , Farina, Juan M. , Abbas, Mohammed Tiseer , Rmilah, Anan Abu , Srivathsan, Komandoor

Mayo Clinic

European Journal of Preventive Cardiology | February 7, 2025 | Volume: 32 | Issue: 9 | Pages: 769-777

10.1093/eurjpc/zwaf063 | PMID 39919039 Get It

Abstract Aims Atrial fibrillation (AF) is the most common cardiac arrhythmia. Although lipoprotein(a) [Lp(a)] is known to be a well-established risk factor for atherosclerotic cardiovascular disease, its role in the development of AF, independent of this association, remains unclear. Methods and results Adult patients from the three Mayo Clinic sites with a baseline Lp(a) and without AF history were included. Patients were categorized into two groups based on their Lp(a) levels: high Lp(a) (≥50 mg/dL) and low Lp(a) (&lt;50 mg/dL). Survival probabilities free from incident AF were compared between Lp(a) groups, during a follow-up period up to 15 years, using the Kaplan–Meier curve and the log-rank test. Multivariable Cox regression analysis was also conducted. A total of 75 376 patients were included (median age: 55 years, 59% males), with a median follow-up duration of 8.8 (inter-quartile range: 3.4, 14.8) years. Incident AF was detected in 5738 (7.6%) patients. Survival probability free from incident AF was significantly lower in patients with elevated Lp(a) (86%) compared with those with low Lp(a) (88%, log-rank P &lt; 0.001). Multivariable analysis adjusted for potential risk factors of AF showed a statistically significant association of elevated Lp(a) with an 11% increase in AF risk (adjusted hazard ratio: 1.11, 95% confidence interval: 1.05–1.18). Conclusion Our study suggests that elevated Lp(a) (≥50 mg/dL) is an independent risk factor for incident AF. Future prospective studies are warranted to validate our results and to test if reducing Lp(a) could mitigate the burden of AF.
Cardioneuroablation for the treatment of reflex syncope and functional bradyarrhythmias: A Scientific Statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS) and th
Aksu, Tolga , Brignole, Michele , Biase, Luigi Di , Deharo, Jean‐Claude , Fanciulli, Alessandra , Fedorowski, Artur , Morillo, Carlos A. , Moya, Angel , Piotrowski, Roman , Sutton, Richard , Sheldon, Robert S. , Vaseghi, Marmar , Pachon, Jose C, Amin, Reshma , Gupta, Dhiraj, Magnano, M , Malik, Varun , Schauerte, Patrick, Shen, Win-Kuang, Acosta, Juan , Calo, Leonardo , Debruyne, Philippe , Di Biase, Luigi , Deharo, Jean Claude , Fanciulli, Alessandra , Fedorowski, Artur , Kulakowski, Piotr , Morillo, Carlos , Moya, Angel , Piotrowski, Roman , Stec, Sebastian , Sutton, Richard , van Dijk, J Gert , Wichterle, Dan , Tse, Hung-Fat , Yao, Yan , Sheldon, Robert , Vaseghi, Marmar , Pachon, Jose C , Scanavacca, Maurício , Tse, Hung‐Fat , Pachón-M, José Carlos , Scanavacca, Maurício , Meyer, Christian , Gupta, Dhiraj

Mayo Clinic

Europace | July 30, 2024 | Volume: 26 | Issue: 8 | Pages: No page available

10.1093/europace/euae206 | PMID 39082698 Get It

Abstract Cardioneuroablation has emerged as a potential alternative to cardiac pacing in selected cases with vasovagal reflex syncope, extrinsic vagally induced sinus bradycardia-arrest or atrioventricular block. The technique was first introduced decades ago, and its use has risen over the past decade. However, as with any intervention, proper patient selection and technique are a prerequisite for a safe and effective use of cardioneuroablation therapy. This document aims to review and interpret available scientific evidence and provide a summary position on the topic.
Abstract 13068: Use of Cardiac Implantable Electronic Devices in Carcinoid Heart Disease
Shabtaie, Samuel A. , Connolly, Heidi M. , Miranda, William R. , Shen, Win-Kuang, Cha, Yong‐Mei , Asirvatham, Samuel, Deshmukh, Abhishek , Ward, Robert C. , Luis, Sushil Allen , Pellikka, Patricia A. , Schaff, Hartzell V. , DeSimone, Christopher V.

Mayo Clinic

Circulation | April 23, 2024 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.13068 Get It

Introduction: Carcinoid heart disease (CHD) is a rare sequelae of hormonally active neuroendocrine tumors that often requires cardiac surgical intervention. Little is reported on cardiac implantable electronic device (CIED) implantation in the CHD patient population. Hypothesis: We sought to establish the safety and efficacy of CIED implantation in patients with CHD. Methods: We retrospectively reviewed patients with a diagnosis of CHD who underwent CIED implantation at our institution (Mayo Clinic) and evaluated indications for implant, perioperative complications, and mortality. Results: A total of 27 patients with a cumulative follow up of 75 patient-years were identified during the study period. The most common indication for device implant was high grade atrioventricular block (n=18, 66.7%). 14 (51.8%) had baseline conduction disease and 26 (96.2%) underwent cardiac surgery prior to CIED implant. The majority of devices implanted were dual chamber permanent pacemakers (PPM) (n=17, 63.0%), while other devices included single chamber PPM, epicardial PPM, chronic resynchronization devices, and intracardiac defibrillators. Peri-operative complication occurred in 6 patients (22.2%), with 2 patients requiring ICU level care. No patient suffered carcinoid crisis during implantation and there was no peri-implant mortality. Long term, 3 patients required device extraction: 1 for infection, 1 for lead related pain, and 1 for generator migration. The median time to death from implant was 2.5 years, with one-year mortality at 15%. Conclusions: In this unique cohort of patients with CHD, CIED can be performed safely. CIED most often occurred in the post cardiac surgical period and carcinoid crisis was uncommon.
Brugada Syndrome in a Transplanted Heart: Implications for Organ Transplant Screening Process
Fatunde, Olubadewa A. , Maleszewski, Joseph J. , Murray, David R. , Shen, Win‐Kuang , Pereira, Naveen L. , Rattanawong, Pattara , Maleszewski, Joseph J , Shen, Win-Kuang , Pereira, Naveen L , Fatunde, Olubadewa A , Rattanawong, Pattara

Mayo Clinic

Circulation: Genomic and Precision Medicine | April 23, 2024 | Volume: 17 | Issue: 3 | Pages: No page available

10.1161/circgen.123.004533 | PMID 38651350 Get It

Abstract 10571: Causes of Early Mortality After Catheter Ablation of Ventricular Tachycardia in Patients With Reduced Left Ventricular Ejection Fraction
Lee, Justin Z. , Deshmukh, Abhishek , Shen, Win K., Scott, Luis R. , Cha, Yong‐Mei , Mulpuru, Siva K. , Tan, Min Choon , Srivathsan, Komandoor , Masry, Hicham El , Asirvatham, Samuel J. , McLeod, Christopher J.

Mayo Clinic

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.10571 Get It

Background: Recognition of the causes of early mortality after ventricular tachycardia (VT) ablation in patients with reduced left ventricular ejection fraction is an essential step toward improving post-procedural outcomes. Objective: This study sought to determine the causes of early mortality (≤30-days) after VT ablation in patients with reduced left ventricular ejection fraction and to understand further the circumstances surrounding death after the procedure. Methods: We performed a retrospective analysis of all patients undergoing VT ablation in patients with reduced left ventricular ejection fraction from January 1, 2013, to November 10, 2021, at the Mayo Clinic (Rochester, Phoenix, and Jacksonville). Causes of death were identified through a detailed chart review of the electronic health record within the Mayo Clinic system and outside records. Results: A total of 503 patients (mean age 63 ± 13 years, 11.2% female) with EF <50% were included in the study. The 30-day all-cause mortality rate was 5% (n=25), and the mortality rate due to a procedural complication was 0.4%. Among all 30-day deaths, recurrent VT was the most common primary cause of death (44%). This was followed by decompensated heart failure (28%), procedure-related death (8%), cerebrovascular accident (CVA) (4%), and infection (4%). Most patients (91%) who died from VT had the VT recurrence within three days of the ablation. 76% of patients with early mortality had delayed referral for VT ablation, and 72% opted for comfort care before death. Conclusions: The overall early mortality (≤30-days) rate after catheter ablation of VT in patients with reduced left ventricular ejection fraction was 5%, but the death rate directly due to a procedural complication was only 0.4%. The most common cause of death was recurrent VT, followed by heart failure. Further research into ablation strategies is vital to improving the safety, efficacy, and durability of VT ablation.